Financial statements Glenmark Pharmaceuticals
Cash flow statement of Glenmark Pharmaceuticals
Company age:
Age:
17 y. 7 m. 6 d.
Share capital:
Share capital:
50 000 PLN
Cash inflows of GLENMARK PHARMACEUTICALS
|
Year
|
2018
|
2019
|
2020
|
2021
|
2023
|
|---|---|---|---|---|---|
| Net cash from operating expenses | -298 656,88 | 1 339 434,23 | 399 349,46 | 6 785 820,26 | -2 607 995,32 |
| Net cash flow from investing activities | -1 126 695,69 | -257 434,59 | -62 200,72 | -377 645,75 | -429 404,43 |
| Net cash flow from financial activities | 0,00 | 0,00 | 0,00 | -546 242,96 | -490 968,53 |
| Total net cash flow | -1 425 352,57 | 1 081 999,64 | 337 148,74 | 5 861 931,55 | -3 528 368,28 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.